SCHEMBL25302510

SCHEMBL25302510

N=C(N)NCCCC(N)C(=O)CC(=O)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ OTC P00480 1/20 0.39
▸ DDAH1 O94760 2/20 0.37
▸ DPP7 Q9UHL4 2/20 0.36
▸ ALOX15 P16050 1/20 0.35
▸ NPY4R P50391 7/20 0.34
▸ NPY1R P25929 5/20 0.34
▸ NPY2R P49146 4/20 0.34
▸ NPY5R Q15761 4/20 0.34
▸ NOS1 P29475 3/20 0.34
▸ NOS3 P29474 2/20 0.34
▸ NOS2 P35228 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ GNAI3 P08754 1/20 0.32
▸ GNAO1 P09471 1/20 0.32
▸ GNAI1 P63096 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30531668 0.87 OTC (0.41) OTCDDAH1DPP7ALOX15NPY4R
SCHEMBL5872308 0.85 DPP7 (0.39) OTCDDAH1DPP7ALOX15NPY4R
Arginine SCHEMBL28975305 0.84 OTC (0.47) OTCDDAH1ALOX15NOS1NOS3
SCHEMBL25303340 0.83 OTC (0.38) OTCDDAH1DPP7ALOX15NPY4R
SCHEMBL30597599 0.83 OTC (0.38) OTCDDAH1DPP7ALOX15NPY4R
SCHEMBL2186467 0.81 DPP7 (0.39) OTCDDAH1DPP7ALOX15NPY4R
Arginine SCHEMBL16194085 0.81 OTC (0.53) OTCDDAH1ALOX15NOS1NOS3
SCHEMBL11814623 0.81 OTC (0.41) OTCDDAH1DPP7ALOX15NPY4R
SCHEMBL19465128 0.81 DPP7 (0.39) OTCDDAH1DPP7ALOX15NPY4R
Arginine SCHEMBL309346 0.81 DPP7 (0.39) OTCDDAH1DPP7ALOX15NPY4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622967-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others TODAY, INC. (US) 2026-05-12 — — US disclosed
US-20240299548-A1 MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS TODAY, INC. (US) 2024-09-12 — — US disclosed
US-12023382-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others Today Inc. (US) 2024-07-02 — — US disclosed
WO-2023139357-A1 MOLECULES, NUTRITIONAL FORMULATIONS, AND METHODS OF PROVIDING NUTRITIONAL SUPPORT Today Inc. (US) 2023-07-27 — — WO disclosed
US-20230226187-A1 MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS Today Inc. (US) 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622967-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others SLC2A9, GYS1, SLC2A8 OTC 354/4885DDAH1 4612/4885DPP7 3324/4885
US-20240299548-A1 MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS CPT1B, GK, CPT1A OTC 2007/4885DDAH1 1958/4885DPP7 4197/4885
US-20230226187-A1 MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS CPT1B, GK, CPT1A OTC 2007/4885DDAH1 1958/4885DPP7 4197/4885
US-12023382-B2 Molecules, formulations, and methods for nutritional support of athletes, patients, and others CPT1B, GK, CPT1A OTC 2007/4885DDAH1 1958/4885DPP7 4197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback